Production (Stage)
Corvus Pharmaceuticals, Inc.
CRVS
$3.49
$0.020.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 15.86% | 4.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.42% | 11.72% | |||
| Operating Income | -22.42% | -11.72% | |||
| Income Before Tax | 225.43% | 69.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 225.43% | 69.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 225.43% | 69.88% | |||
| EBIT | -22.42% | -11.72% | |||
| EBITDA | -22.45% | -11.76% | |||
| EPS Basic | 218.85% | 70.61% | |||
| Normalized Basic EPS | 218.86% | 70.59% | |||
| EPS Diluted | 25.40% | 70.61% | |||
| Normalized Diluted EPS | 214.08% | 70.59% | |||
| Average Basic Shares Outstanding | 5.53% | 2.47% | |||
| Average Diluted Shares Outstanding | 9.96% | 2.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||